Compare Novavax Inc (NVAX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while ProShares UltraPro Short QQQ ETF trades at $38.76. The key difference: Novavax Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| NVAX | SQQQ | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.19 | $89.43 |
52-Week Low | $6.22 | $36.04 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are predominantly bearish, with moving averages signaling sell and oscillators neutral. The ETF is designed to gain when the Nasdaq-100 declines, but its structure leads to value erosion over time due to daily resets. Recent news highlights its use as a tactical hedge amid tech sector volatility but warns of long-term unsuitability.
The outlook for SQQQ is highly speculative and short-term oriented. It may offer tactical gains if tech stocks weaken, but structural decay and high volatility pose significant risks. Investors should view it as a hedging tool rather than a long-term holding, with success dependent on precise market timing and active management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
